Updates are available Correction dated 2025-04-24

Article History

Accepted: 3 February 2025

First Online: 5 March 2025

Change Date: 24 April 2025

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1007/s40257-025-00948-6

Declarations

:

: No funding was received for the preparation of this article.

: Amalie Thorsti Møller Rønnstad has received research funding from the Department of Clinical Medicine, Copenhagen University and the Kgl Hofbundtmager Aage Bang Foundation. Masahiro Kamata received honoraria for lectures from LEO Pharma, AbbVie, Eli Lilly, Janssen, UCB, Boehringer Ingelheim, Bristol Myers Squibb, Kyowa Kirin, Torii, Taiho and Maruho. Mia-Louise Nielsen has received consultancy honoraria from LEO Pharma. Simon F. Thomsen has received research support from Janssen, LEO Pharma, Novartis, Sanofi and UCB, and has been a speaker/consultant for AbbVie, CSL, Eli Lilly, Janssen, Galderma, Incyte, LEO Pharma, Novartis, Pfizer, Sanofi, Symphogen, UCB and Union Therapeutics. Christian Vestergaard has been an investigator for AbbVie A/S, Pierre Fabre Dermo-Cosmetique, Novartis, LEO Pharma, Sanofi, Almirall, Galderma and Pfizer. He has served on advisory boards for Astellas Pharma, Almirall, Sanofi, Abb-Vie, Galderma, Leo Pharma and MEDA, and has been a speaker for Leo-Pharma, Astellas, MSD, AbbVie, Novartis Almirall, Sanofi and Pfizer. Raj Chovatiya served as an advisor, consultant, speaker and/or investigator for AbbVie, Amgen, AnaptysBio, Apogee Therapeutics, Arcutis, Argenx, ASLAN Pharmaceuticals, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, FIDE, Formation Bio, Galderma, Genentech, GSK, Incyte, LEO Pharma, L’Oréal, Nektar Therapeutics, Novartis, Opsidio, Pfizer Inc., RAPT, Regeneron, Sanofi, Sitryx, Takeda, TRexBio and UCB. Christopher G. Bunick has served as an investigator for AbbVie, Almirall, Apogee, Daiichi Sankyo, LEO Pharma, Ortho Dermatologics, Sun Pharma, Timber and Palvella, a consultant for AbbVie, Almirall, Apogee, Arcutis, Connect BioPharma, Eli Lilly, EPI Health/Novan, Incyte, LEO Pharma, Novartis, Ortho Dermatologics, Pfizer, Sanofi-Regeneron, Takeda and UCB, and a speaker for and received honoraria from Allergan, Almirall, LEO Pharma, and UCB. Andreas Wollenberg has served as an advisor or paid speaker for, or participated in clinical trials (with honoraria paid to the institution) sponsored by AbbVie, Aileens, Almirall, Amgen, Beiersdorf, Bioderma, Bioproject, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Chugai, DKSH, Eli Lilly, Galapagos, Galderma, Glenmark, GSK, Hans Karrer, Hexal, Janssen-Cilag, Kyowa Kirin, Leo Pharma, L’Oreal, Maruho, MedImmune, MSD, Mylan, MSD, Novartis, Pfizer, Pierre Fabre, Regeneron, Sandoz, Santen, Sanofi-Aventis and UCB. Alexander Egeberg has received research funding from Almirall, Pfizer, Eli Lilly, Novartis, Bristol-Myers Squibb, AbbVie, Janssen Pharmaceuticals, Boehringer Ingelheim, the Danish National Psoriasis Foundation, the Simon Spies Foundation and the Kgl Hofbundtmager Aage Bang Foundation, and honoraria as a consultant and/or speaker from Amgen, AbbVie, Almirall, Leo Pharma, Zuellig Pharma Ltd., Galápagos NV, Sun Pharmaceuticals, Samsung Bioepis Co., Ltd., Pfizer, Eli Lilly and Company, Novartis, Union Therapeutics, Galderma, Dermavant, UCB, Mylan, Bristol-Myers Squibb, McNeil Consumer Healthcare, Horizon Therapeutics, Boehringer Ingelheim and Janssen Pharmaceuticals. He is currently an employee at LEO Pharma. Jacob P. Thyssen has been an advisor for AbbVie, Almirall, Arena Pharmaceuticals, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron and Sanofi-Genzyme, and received research grants from Pfizer, Regeneron and Sanofi-Genzyme. He is currently an employee at LEO Pharma. Nikolai Loft has been a paid speaker for Eli Lilly, Janssen Cilag and Sandoz, and received research funding from the LEO Foundation.

: Not applicable.

: Not applicable.

: Not applicable.

: Data and material are available upon request.

: The code is available upon request.

: NL, DI, ATMR and M-LN had full access to all the data in the study and take full responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: NL, CGB, RC, JPT and AE. Acquisition, analysis and interpretation of data: all authors. Drafting of the manuscript: NL and ATMR. Critical revision of the manuscript for important intellectual content: all authors. Statistical analysis: M-LN. Administrative, technical or material support: none. All authors read and approved the final manuscript.